Department of Paediatrics, Royal Derbyshire Hospital, Derby, UK.
Department of Pharmacy, Glenfield Hospital, Leicester, UK.
Arch Dis Child. 2014 Sep;99(9):873-7. doi: 10.1136/archdischild-2013-304467. Epub 2014 Jun 17.
Intravenous salbutamol is commonly used to treat children with severe asthma unresponsive to inhaled β2-agonist therapy. However, in this setting, there is little clinical trial data demonstrating its effectiveness. Additionally, there are significant concerns that intravenous salbutamol-dosing recommendations for children with acute asthma are excessive, and unnecessarily raise the potential for adverse reactions, such as lactic acidosis and tachycardia which, by increasing respiratory workload, exacerbate respiratory failure. Here, we review salbutamol clinical pharmacology and toxicology, evidence relating to its use in acute asthma and highlight gaps in the evidence base.
静脉注射沙丁胺醇常用于治疗对吸入β2-激动剂治疗无反应的严重哮喘儿童。然而，在这种情况下，几乎没有临床试验数据证明其有效性。此外，人们非常担心急性哮喘儿童静脉注射沙丁胺醇的剂量建议过高，不必要地增加了不良反应的风险，如乳酸酸中毒和心动过速，这会增加呼吸负荷，加重呼吸衰竭。在这里，我们回顾了沙丁胺醇的临床药理学和毒理学，以及与急性哮喘使用相关的证据，并强调了证据基础中的差距。
